# Cydectin Long Acting Injection for Sheep Virbac (Australia) Pty Limited

Chemwatch: 6069982 Version No: 6.1.16.10

Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

# Chemwatch Hazard Alert Code: 2

Issue Date: 11/01/2019 Print Date: 08/31/2021 L.GHS.AUS.EN

# SECTION 1 Identification of the substance / mixture and of the company / undertaking

# Product name Cydectin Long Acting Injection for Sheep Chemical Name Not Applicable Synonyms APVMA No.: 58532 Chemical formula Not Applicable Other means of identification Not Available

# Relevant identified uses of the substance or mixture and uses advised against

# Details of the supplier of the safety data sheet

Registered company name	Virbac (Australia) Pty Limited	
Address	Address 361 Horsley Road Milperra NSW 2214 Australia	
Telephone	1800 242 100	
Fax	Fax +61 2 9772 9773	
Website au.virbac.com		
Email	Email au_customerservice@virbac.com.au	

# Emergency telephone number

Association / Organisation	Poisons Information Centre
Emergency telephone numbers	13 11 26
Other emergency telephone numbers	Not Available

# **SECTION 2 Hazards identification**

# Classification of the substance or mixture

# HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. According to the WHS Regulations and the ADG Code.

# ChemWatch Hazard Ratings

	Min	Max	
Flammability	1		
Toxicity	2		0 = Minimum
Body Contact	2	1	1 = Low
Reactivity	1	- 1	2 = Moderate
Chronic	2		3 = High 4 = Extreme

Poisons Schedule S5	
Classification <sup>[1]</sup>	Serious Eye Damage/Eye Irritation Category 2A, Reproductive Toxicity Category 2, Specific Target Organ Toxicity - Repeated Exposure Category 2, Skin Corrosion/Irritation Category 2
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

# Label elements

Hazard pictogram(s)





Signal word Warning

# Hazard statement(s)

nazard statement(s)	
H319	Causes serious eye irritation.
H361fd	Suspected of damaging fertility. Suspected of damaging the unborn child.

Chemwatch: 6069982 Page 2 of 12

Version No: **6.1.16.10** 

# **Cydectin Long Acting Injection for Sheep**

Issue Date: 11/01/2019
Print Date: 08/31/2021

H373	May cause damage to organs through prolonged or repeated exposure.
H315	Causes skin irritation.

#### Precautionary statement(s) Prevention

P201	Obtain special instructions before use.	
P260 Do not breathe mist/vapours/spray.		
P280 Wear protective gloves, protective clothing, eye protection and face protection.		
P264	Wash all exposed external body areas thoroughly after handling.	

# Precautionary statement(s) Response

P308+P313	IF exposed or concerned: Get medical advice/ attention.	
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.	
P314	P314 Get medical advice/attention if you feel unwell.	
P337+P313	If eye irritation persists: Get medical advice/attention.	
P302+P352	P352 IF ON SKIN: Wash with plenty of water.	
P332+P313 If skin irritation occurs: Get medical advice/attention.		
P362+P364 Take off contaminated clothing and wash it before reuse.		

#### Precautionary statement(s) Storage

P405 Store locked up.

#### Precautionary statement(s) Disposal

P501

Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

# **SECTION 3 Composition / information on ingredients**

#### Substances

See section below for composition of Mixtures

#### **Mixtures**

CAS No	%[weight]	Name
113507-06-5	2-3	moxidectin
Not Available		(22.22g/L)
Not Available	1-10	Ingredients determined not to be hazardous
57-55-6	255-6 >60 propylene glycol  Legend: 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L * EU IOELVs available	
Legend:		

# **SECTION 4 First aid measures**

# Description of first aid measures

Wash out imme

**Eye Contact** 

- If this product comes in contact with the eyes:
- Wash out immediately with fresh running water.
- Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
- Seek medical attention without delay; if pain persists or recurs seek medical attention.
- Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.

# Skin Contact

WARNING: AVOID SELF-INJECTION. Accidental self-injection may cause a persistent inflammatory or an allergic response. Medical advice should be sought as soon as possible on the management of all instances of self-injection, especially deep injections, those near a joint or those associated with bruising. The application of gentle pressure with absorbent material, e.g. facial tissues, to the needle puncture area will swab up unabsorbed product. Strong squeezing of the site should be avoided. The damaged area should be thoroughly cleansed and a suitable antiseptic applied.

If skin or hair contact occurs:

- Flush skin and hair with running water (and soap if available).
- Seek medical attention in event of irritation.

# Inhalation

► Other measures are usually unnecessary.

If fumes, aerosols or combustion products are inhaled remove from contaminated area.

- ► IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY.
  ► For advice, contact a Poisons Information Centre or a doctor.
- For advice, contact a Poisons information Centr
   Urgent hospital treatment is likely to be needed.
- In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition.
- If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the SDS should be provided. Further action will be the responsibility of the medical specialist.
- F If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the SDS.

# Ingestion

Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:

• INDUCE vomiting with fingers down the back of the throat, ONLY IF CONSCIOUS. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.

**NOTE:** Wear a protective glove when inducing vomiting by mechanical means.

Issue Date: 11/01/2019 Chemwatch: 6069982 Page 3 of 12 Version No: 6.1.16.10

# Cydectin Long Acting Injection for Sheep

Print Date: 08/31/2021

# Indication of any immediate medical attention and special treatment needed

As in all cases of suspected poisoning, follow the ABCDEs of emergency medicine (airway, breathing, circulation, disability, exposure), then the ABCDEs of toxicology (antidotes, basics, change absorption, change distribution, change elimination).

For poisons (where specific treatment regime is absent):

#### BASIC TREATMENT

- ▶ Establish a patent airway with suction where necessary.
- Watch for signs of respiratory insufficiency and assist ventilation as necessary.
- Administer oxygen by non-rebreather mask at 10 to 15 L/min
- Monitor and treat, where necessary, for pulmonary oedema.
- Monitor and treat, where necessary, for shock.
- Anticipate seizures
- DO NOT use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.

#### ADVANCED TREATMENT

▶ Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.

- Positive-pressure ventilation using a bag-valve mask might be of use
- Monitor and treat, where necessary, for arrhythmias.
- Start an IV D5W TKO. If signs of hypovolaemia are present use lactated Ringers solution. Fluid overload might create complications.
- Drug therapy should be considered for pulmonary oedema.
- Hypotension with signs of hypovolaemia requires the cautious administration of fluids. Fluid overload might create complications
- Treat seizures with diazepam.
- Proparacaine hydrochloride should be used to assist eye irrigation.

BRONSTEIN, A.C. and CURRANCE, P.L.

EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994

For abamectin (avermectins):

Toxicity following accidental ingestion may be minimised by emesis-induction within one half hour of exposure. Since abamectin is thought to bind to glutamate-gated chloride ion channels, it is probably wise to avoid drugs that also interact with other ligand-gated chloride channels, including those that enhance GABA activity in patients with potentially toxic abamectin exposure

Avoid drugs that enhance GABA activity (barbiturate, benzodiazepines, valproic acid, etc.).

# **SECTION 5 Firefighting measures**

# **Extinguishing media**

- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide
- ▶ Water spray or fog Large fires only.

# Special hazards arising from the substrate or mixture

Fire Incompatibility Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

# Advice for firefighters

Fire Fighting	<ul> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear full body protective clothing with breathing apparatus.</li> <li>Prevent, by any means available, spillage from entering drains or water course.</li> <li>Use fire fighting procedures suitable for surrounding area.</li> <li>Do not approach containers suspected to be hot.</li> <li>Cool fire exposed containers with water spray from a protected location.</li> <li>If safe to do so, remove containers from path of fire.</li> <li>Equipment should be thoroughly decontaminated after use.</li> </ul>
Fire/Explosion Hazard	<ul> <li>Combustible.</li> <li>Slight fire hazard when exposed to heat or flame.</li> <li>Heating may cause expansion or decomposition leading to violent rupture of containers.</li> <li>On combustion, may emit toxic fumes of carbon monoxide (CO).</li> <li>May emit acrid smoke.</li> <li>Mists containing combustible materials may be explosive.</li> <li>Combustion products include:</li> <li>carbon dioxide (CO2)</li> <li>other pyrolysis products typical of burning organic material.</li> <li>May emit poisonous fumes.</li> </ul>

# HAZCHEM **SECTION 6 Accidental release measures**

# Personal precautions, protective equipment and emergency procedures

Not Applicable

See section 8

# **Environmental precautions**

See section 12

# Methods and material for containment and cleaning up

Minor Spills

Remove all ignition sources

Chemwatch: 6069982 Page 4 of 12 Issue Date: 11/01/2019 Version No: 6.1.16.10 Print Date: 08/31/2021

# **Cydectin Long Acting Injection for Sheep**

Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. ▶ Control personal contact with the substance, by using protective equipment. ▶ Contain and absorb spill with sand, earth, inert material or vermiculite. ► Wipe up. Place in a suitable, labelled container for waste disposal. Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear full body protective clothing with breathing apparatus. Prevent, by any means available, spillage from entering drains or water course. Stop leak if safe to do so. ► Contain spill with sand, earth or vermiculite. **Major Spills** Collect recoverable product into labelled containers for recycling. ▶ Neutralise/decontaminate residue (see Section 13 for specific agent). Collect solid residues and seal in labelled drums for disposal. Wash area and prevent runoff into drains. After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

# **SECTION 7 Handling and storage**

Precautions for safe handling			
Safe handling	<ul> <li>Avoid all personal contact, including inhalation.</li> <li>Wear protective clothing when risk of exposure occurs.</li> <li>Use in a well-ventilated area.</li> <li>Prevent concentration in hollows and sumps.</li> <li>DO NOT enter confined spaces until atmosphere has been checked.</li> <li>DO NOT allow material to contact humans, exposed food or food utensils.</li> <li>Avoid contact with incompatible materials.</li> <li>When handling, DO NOT eat, drink or smoke.</li> <li>Keep containers securely sealed when not in use.</li> <li>Avoid physical damage to containers.</li> <li>Always wash hands with soap and water after handling.</li> <li>Work clothes should be laundered separately. Launder contaminated clothing before re-use.</li> <li>Use good occupational work practice.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.</li> </ul>		
Other information	<ul> <li>Store in original containers.</li> <li>Keep containers securely sealed.</li> <li>Store in a cool, dry, well-ventilated area.</li> <li>Store away from incompatible materials and foodstuff containers.</li> <li>Protect containers against physical damage and check regularly for leaks.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul>		

# Conditions for safe storage, including any incompatibilities

Suitable container	<ul> <li>Lined metal can, lined metal pail/ can.</li> <li>Plastic pail.</li> <li>Polyliner drum.</li> <li>Packing as recommended by manufacturer.</li> <li>Check all containers are clearly labelled and free from leaks.</li> </ul>
Storage incompatibility	<ul> <li>Avoid reaction with oxidising agents</li> <li>Avoid strong acids, acid chlorides, acid anhydrides and chloroformates.</li> </ul>

# SECTION 8 Exposure controls / personal protection

# **Control parameters**

# Occupational Exposure Limits (OEL)

# INGREDIENT DATA

1 ····································						
Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	propylene glycol	Propane-1,2-diol: particulates only	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	propylene glycol	Propane-1,2-diol total: (vapour & particulates)	150 ppm / 474 mg/m3	Not Available	Not Available	Not Available

# **Emergency Limits**

Ingredient	TEEL-1	TEEL-2	TEEL-3
propylene glycol	30 mg/m3	330 mg/m3	2,000 mg/m3
propylene glycol	30 mg/m3	1,300 mg/m3	7,900 mg/m3

Ingredient	Original IDLH	Revised IDLH
moxidectin	Not Available	Not Available
propylene glycol	Not Available	Not Available

# Occupational Exposure Banding

Chemwatch: 6069982 Page 5 of 12

Version No: 6.1.16.10 Cudastin Large Acting Injection for Channel

#### Cydectin Long Acting Injection for Sheep

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit	
moxidectin	E	≤ 0.01 mg/m³	
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.		

#### MATERIAL DATA

#### **Exposure controls**

# For potent pharmacological agents:

#### **Powders**

To prevent contamination and overexposure, no open handling of powder should be allowed.

- Powder handling operations are to be done in a powders weighing hood, a glove box, or other equivalent ventilated containment system.
- In situations where these ventilated containment hoods have not been installed, a non-ventilated enclosed containment hood should be used.
- Pending changes resulting from additional air monitoring data, up to 300 mg can be handled outside of an enclosure provided that no grinding, crushing or other dust-generating process occurs.
- An air-purifying respirator should be worn by all personnel in the immediate area in cases where non-ventilated containment is used, where significant amounts of material (e.g., more than 2 grams) are used, or where the material may become airborne (as through grinding, etc.).
- Powder should be put into solution or a closed or covered container after handling.
- If using a ventilated enclosure that has not been validated, wear a half-mask respirator equipped with HEPA cartridges until the enclosure is validated for use.

#### Solutions Handling:

- Solutions can be handled outside a containment system or without local exhaust ventilation during procedures with no potential for aerosolisation. If the procedures have a potential for aerosolisation, an air-purifying respirator is to be worn by all personnel in the immediate area.
- Solutions used for procedures where aerosolisation may occur (e.g., vortexing, pumping) are to be handled within a containment system or with local exhaust ventilation.
- In situations where this is not feasible (may include animal dosing), an air-purifying respirator is to be worn by all personnel in the immediate area. If using a ventilated enclosure that has not been validated, wear a half-mask respirator equipped with HEPA cartridges until the enclosure is validated for use.
- ▶ Ensure gloves are protective against solvents in use.

Enclosed local exhaust ventilation is required at points of dust, fume or vapour generation.

HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours.

Barrier protection or laminar flow cabinets should be considered for laboratory scale handling.

A fume hood or vented balance enclosure is recommended for weighing/ transferring quantities exceeding 500 mg.

When handling quantities up to 500 gram in either a standard laboratory with general dilution ventilation (e.g. 6-12 air changes per hour) is preferred. Quantities up to 1 kilogram may require a designated laboratory using fume hood, biological safety cabinet, or approved vented enclosures. Quantities exceeding 1 kilogram should be handled in a designated laboratory or containment laboratory using appropriate barrier/containment technology.

Manufacturing and pilot plant operations require barrier/ containment and direct coupling technologies.

# Appropriate engineering controls

Barrier/ containment technology and direct coupling (totally enclosed processes that create a barrier between the equipment and the room) typically use double or split butterfly valves and hybrid unidirectional airflow/ local exhaust ventilation solutions (e.g. powder containment booths). Glove bags, isolator glove box systems are optional. HEPA filtration of exhaust from dry product handling areas is required.

Fume-hoods and other open-face containment devices are acceptable when face velocities of at least 1 m/s (200 feet/minute) are achieved. Partitions, barriers, and other partial containment technologies are required to prevent migration of the material to uncontrolled areas. For non-routine emergencies maximum local and general exhaust are necessary. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, etc. evaporating from tank (in still air)	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2.5 m/s (200-500 f/min.) for extraction of gases discharged 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated: Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated.

The following protective devices are recommended where exposures exceed the recommended exposure control guidelines by factors of:

Issue Date: 11/01/2019

Print Date: 08/31/2021

Chemwatch: 6069982 Page 6 of 12 Issue Date: 11/01/2019 Version No: 6.1.16.10

#### Cydectin Long Acting Injection for Sheep

Print Date: 08/31/2021

10; high efficiency particulate (HEPA) filters or cartridges

10-25; loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator.

25-50; a full face-piece negative pressure respirator with HEPA filters

50-100; tight-fitting, full face-piece HEPA PAPR

100-1000; a hood-shroud HEPA PAPR or full face-piece supplied air respirator operated in pressure demand or other positive pressure mode.

#### Personal protection











# Eye and face protection

For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

- Chemical goggles
- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

#### Skin protection

See Hand protection below

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice

Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:

- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and
- dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).

- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.
- Contaminated gloves should be replaced.

As defined in ASTM F-739-96 in any application, gloves are rated as:

- Excellent when breakthrough time > 480 min
  - Good when breakthrough time > 20 min Fair when breakthrough time < 20 min
  - Poor when glove material degrades

For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.

It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.

Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers' technical data should always be taken into account to ensure selection of the most appropriate glove for the task

Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:

- Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.
- Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended

- ▶ Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference
- ▶ Double gloving should be considered.
- PVC gloves.
- ▶ Change gloves frequently and when contaminated, punctured or torn.
- Wash hands immediately after removing gloves.
- Protective shoe covers. [AS/NZS 2210]
- Head covering.

# **Body protection**

Other protection

Hands/feet protection

See Other protection below

- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Ensure there is ready access to an emergency shower.
- ▶ For Emergencies: Vinyl suit

# Recommended material(s) **GLOVE SELECTION INDEX**

# Respiratory protection

Chemwatch: **6069982** Page **7** of **12** 

Version No: 6.1.16.10

# **Cydectin Long Acting Injection for Sheep**

Issue Date: 11/01/2019
Print Date: 08/31/2021

#### "Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

Cydectin Long Acting Injection for Sheep

Material	СРІ
BUTYL	С
NATURAL RUBBER	С
NEOPRENE	С
PE/EVAL/PE	С
PVA	С
VITON	С

- \* CPI Chemwatch Performance Index
- A: Best Selection
- B: Satisfactory; may degrade after 4 hours continuous immersion
- C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

\* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 5 x ES	A-AUS / Class 1 P2	-	A-PAPR-AUS / Class 1 P2
up to 25 x ES	Air-line*	A-2 P2	A-PAPR-2 P2
up to 50 x ES	-	A-3 P2	-
50+ x ES	-	Air-line**	-

\* - Continuous-flow; \*\* - Continuous-flow or positive pressure demand ^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

# **SECTION 9 Physical and chemical properties**

# Information on basic physical and chemical properties

Appearance	Liquid.		
Dhysical state	I tanka	Deletive density (Meter 4)	0.005.0.007
Physical state	Liquid	Relative density (Water = 1)	0.935-0.937
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Applicable	Decomposition temperature	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Available	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Not Available	pH as a solution (%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

# **SECTION 10 Stability and reactivity**

Reactivity	See section 7
Chemical stability	<ul> <li>Unstable in the presence of incompatible materials.</li> <li>Product is considered stable.</li> <li>Hazardous polymerisation will not occur.</li> </ul>
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

# **SECTION 11 Toxicological information**

Chemwatch: **6069982** Page **8** of **12** 

Version No: 6.1.16.10 Cydectin Long Acting Injection for Sheep

Information on toxicological effects

#### The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other Inhaled route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may Ingestion produce serious damage to the health of the individual. Skin contact is not thought to produce harmful health effects (as classified under EC Directives using animal models). Systemic harm, however, has been identified following exposure of animals by at least one other route and the material may still produce health damage following entry through wounds, lesions or abrasions. Good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an Skin Contact occupational setting. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected. Although the liquid is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort Eve characterised by tearing or conjunctival redness (as with windburn) Harmful: danger of serious damage to health by prolonged exposure if swallowed. Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may Chronic become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems TOXICITY IRRITATION **Cydectin Long Acting** Injection for Sheep Not Available Not Available TOXICITY IRRITATION Dermal (rabbit) LD50: >2000 mg/kg<sup>[2]</sup> Eve (rabbit): slight irritant \* moxidectin Oral(Mouse) LD50; 42 mg/kg<sup>[2]</sup> Skin (rabbit): non-irritant \* TOXICITY IRRITATION Dermal (rabbit) LD50: >2000 mg/kg<sup>[1]</sup> Eye (rabbit): 100 mg - mild Inhalation(Rat) LC50; >44.9 mg/L4h[2] Eye (rabbit): 500 mg/24h - mild Oral(Rat) LD50; >10400 mg/kg<sup>[2]</sup> Eye: no adverse effect observed (not irritating)[1]propylene glycol Skin(human):104 mg/3d Intermit Mod Skin(human):500 mg/7days mild Skin: no adverse effect observed (not irritating) $^{[1]}$ Legend: 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.\* Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

For avermectins:

Technical avermectin exhibits high mammalian acute toxicity. In vertebrates, the effects occur via poisoning of the central nervous system (CNS) through reactions at the receptor for the inhibitory neurotransmitter GABA. The avermectins open the GABAA receptor chloride channel by binding to the GABA recognition site (receptor protein) and act as partial agonists.. Chloride ions then flow into the postsynaptic neuron. This chloride permeability increase can significantly hyperpolarize (make more negative) the membrane potential, which has a dampening effect on nerve impulse firing. There is also a reversible dose-dependent increase in chloride ion permeability in response to very low doses of avermectins.

In GABA-insensitive neurons with no inhibitory innervation, the avermectins induce an irreversible increase in chloride ion conductance through interacting with voltage-dependent chloride channels. Avermectin intoxication in mammals begins with hyperexcitability, tremors, and incoordination and later develops into ataxia and coma-like sedation. This is similar to the mode of action of ethanol and barbiturates and benzodiazepine sedatives. However, the avermectins are less specific in their action and can affect a variety of other ligand- and voltage-gated chloride channels. The general safety of the avermectins depends on the presence of an intact P-glycoprotein blood-brain barrier. Avermectin is not considered to be mutagenic and does not sensitise skin. It is not readily absorbed by mammals and the majority of the residue is excreted in the faeces within 2 days. The 24-month rat chronic feeding/ oncogenicity study and 94-week mouse chronic toxicity oncogenicity study were negative for oncogenic potential. The results of a series of developmental toxicity studies (rat, rabbit, mouse) have been evaluated and showed that avermectin B1 produces developmental toxicity (cleft palate) in the CF1 mouse. Toxicology data were also evaluated for the delta-8,9-isomer of avermectin B1 which is a plant photodegradate that can range between 5 and 20 percent of the residue on/in cottonseed. This isomer possesses avermectin-like toxicological activity. It was concluded that the delta 8,9-isomer also produces developmental toxicity (cleft palate) in mice, but not in rats. In addition to avermectin and its delta 8,9-isomer, toxicology data were also evaluated for the "polar degradates" of avermectin, which constitute a large percentage (up to 70%) of the total residue on cottonseed. Review of the toxicology data indicated that these polar degradates do not possess avermectin-like toxicological activity and for this reason need not be included in the tolerance expression for residues in/on cottonseed.

MOXIDECTIN

Abamectin (a mixture of avermectin isomers) is a reproductive toxin in laboratory animals at doses which are acutely toxic to the mother. In development toxicity studies with abamectin, cleft palates were seen in mice and rabbits and clubbing of the forepaws was seen in rabbits. The no-observed-adverse-effect-level (NOAEL) for maternal and developmental toxicity in rabbits was 1 mg/kg/day. In CF-1 mice, a strain recognised to be particularly sensitive to avermectins, the NOAEL for maternal toxicity was 0.05 mg/kg/day and the NOAEL for malformations was 0.2 mg/kg/day. Studies show that the sensitivity of a subpopulation of CF-1 mice to avermectins is due to the absence of a transmembrane P-glycoprotein, a significant component of the blood-brain interface that normally acts as a non-selective protective barrier in a wide range of species including humans. CF-1 mice are therefore an unlikely candidate for assessing human risk. No evidence of developmental toxicity was seen in oral studies in rats in the absence of maternal toxicity (NOAEL = 1.6 mg/kg/day). In a rat multigenerational reproduction study, pup toxicity and deaths were seen at 0.4 mg/kg/day (NOAEL = 0.12 mg/kg/day). Neonatal rats are not an appropriate model for assessing human risk in humans because (a) rat milk has a greater fat content than human breast milk and abamectin concentrates in fat; (b) on a weight basis, the neonatal rat consumes significantly greater quantities of milk than the newborn human and( c) the blood brain barrier in rodents is formed

Issue Date: 11/01/2019

Print Date: 08/31/2021

Chemwatch: 6069982 Page 9 of 12 Issue Date: 11/01/2019 Version No: 6.1.16.10

# Cydectin Long Acting Injection for Sheep

Print Date: 08/31/2021

post-natally (as evidenced by low P-glycoprotein levels) while in humans this membrane is formed pre-natally.

Ivermectin, a close structural analogue, has been used extensively in the treatment of human onchocerciasis at an oral therapeutic dose of 0.2 mg/kg, without serious drug-related effects. Despite its wide usage in animals and humans, ivermectin does dot appear to produce birth defects. Abamectin is non-mutagenic in the Ames test and the micronucleus test.

Dietary carcinogenicity studies in mice and rats showed negative results. In a 14-week oral study in monkeys no effects were seen at 0.2, 0.5 or 1.0 mg/kg/day; emesis was seen at 2.0 mg/kg/day; delayed pupillary obstruction at 6 and 8 mg/kg/day and mydriasis at 12 mg/kg/day In chronic oral toxicity, abamectin produced decreased body weight gain in mice (no-observed-adverse-effect-level (NOAEL) = 1.5 mg/kg/day); tremors in rats (NOAEL = 1.5 mg/kg/day), weight loss, tremors, mydriasis, liver and gall bladder changes and death in dogs (NOAEL = 0.25 mg/kg/day); and emesis, mydriasis and sedation in monkeys (NOAL = 1 mg/kg/day).

May produce developmental toxicity in rat offspring at maternally toxic doses. This does not occur in rabbits. \* \* Cyanamid The ADI for Moxidectin is set at 0.01mg/kg/day. The corresponding NOEL is set at 1mg/kg/day. ADI means Acceptable Daily Intake and NOEL means No-observableeffect-level. In rats given oral doses of moxidectin, decreased activity, prostration, tremors, chromodacryorrhea, decreased respiration, diarrhoea, hypersensitivity to touch and sound, and epistaxis occurred. Congestion of the liver, kidneys and lungs were observed in animals that died, but animals which were sacrificed at the end of the 14-day observation period showed no abnormalities. No overt signs of toxicity were noted in rabbits treated dermally with moxidectin. Studies of moxidectin show the side effects vary by animal and may be affected by the product's formulation, application method and dosage. An overdose of moxidectin enhances the effect of gamma-aminobutyric acid (GABA) in the central nervous system. In horses, overdose may lead to depression, drooping of the lower lip, tremor, lack of coordination when moving (ataxia), decreased rate of breathing (respiratory rate), stupor and coma, If a dog licks moxidectin from the skin which was applied as a "spot-on" (topical) treatment, this has the same effect as an overdose, and may cause vomiting, salivation and neurological signs such as ataxia, tremor, and nystagmus Collie dogs cannot be administered moxidectin

The acute oral toxicity of propylene glycol is very low, and large quantities are required to cause perceptible health damage in humans. Serious toxicity generally occurs only at plasma concentrations over 1 g/L, which requires extremely high intake over a relatively short period of time. It would be nearly impossible to reach toxic levels by consuming foods or supplements, which contain at most 1 g/kg of PG. Cases of propylene glycol poisoning are usually related to either inappropriate intravenous administration or accidental ingestion of large quantities by children. The potential for long-term oral toxicity is also low. Because of its low chronic oral toxicity, propylene glycol was classified by the U. S. Food and Drug Administration as "generally recognized as safe" (GRAS) for use as a direct food additive.

Prolonged contact with propylene glycol is essentially non-irritating to the skin. Undiluted propylene glycol is minimally irritating to the eye, and can produce slight transient conjunctivitis (the eye recovers after the exposure is removed). Exposure to mists may cause eye irritation, as well as upper respiratory tract irritation. Inhalation of the propylene glycol vapours appears to present no significant hazard in ordinary applications. However, limited human experience indicates that inhalation of propylene glycol mists could be irritating to some individuals It is therefore recommended that propylene glycol not be used in applications where inhalation exposure or human eye contact with the spray mists of these materials is likely, such as fogs for theatrical productions or antifreeze solutions for emergency eye wash stations.

Propylene glycol is metabolised in the human body into pyruvic acid (a normal part of the glucose-metabolism process, readily converted to energy), acetic acid (handled by ethanol-metabolism), lactic acid (a normal acid generally abundant during digestion), and propionaldehyde (a potentially hazardous substance).

Propylene glycol shows no evidence of being a carcinogen or of being genotoxic.

Research has suggested that individuals who cannot tolerate propylene glycol probably experience a special form of irritation, but that they only rarely develop allergic contact dermatitis. Other investigators believe that the incidence of allergic contact dermatitis to propylene glycol may be greater than 2% in patients with eczema.

One study strongly suggests a connection between airborne concentrations of propylene glycol in houses and development of asthma and allergic reactions, such as rhinitis or hives in children

PROPYLENE GLYCOL

Another study suggested that the concentrations of PGEs (counted as the sum of propylene glycol and glycol ethers) in indoor air, particularly bedroom air, is linked to increased risk of developing numerous respiratory and immune disorders in children, including asthma, hay fever, eczema, and allergies, with increased risk ranging from 50% to 180%. This concentration has been linked to use of water-based paints and water-based system cleansers.

Patients with vulvodynia and interstitial cystitis may be especially sensitive to propylene glycol. Women suffering with yeast infections may also notice that some over the counter creams can cause intense burning. Post menopausal women who require the use of an eostrogen cream may notice that brand name creams made with propylene glycol often create extreme, uncomfortable burning along the vulva and perianal area. Additionally, some electronic cigarette users who inhale propylene glycol vapor may experience dryness of the throat or shortness of breath. As an alternative, some suppliers will put Vegetable Glycerin in the "e-liquid" for those who are allergic (or have bad reactions) to propylene glycol. Adverse responses to intravenous administration of drugs which use PG as an excipient have been seen in a number of people, particularly with large dosages thereof. Responses may include "hypotension, bradycardia... QRS and T abnormalities on the ECG, arrhythmia, cardiac arrest, serum hyperosmolality, lactic acidosis, and haemolysis". A high percentage (12% to 42%) of directly-injected propylene glycol is eliminated/secreted in urine unaltered depending on dosage, with the remainder appearing in its glucuronide-form. The speed of renal filtration decreases as dosage increases, which may be due to propylene glycol's mild anesthetic / CNS-depressant -properties as an alcohol. In one case, intravenous administration of propylene glycol-suspended nitroglycerin to an elderly man may have induced coma and acidosis. Propylene glycol is an approved food additive for dog food under the category of animal feed and is generally recognized as safe for dogs with an LD50 of 9 mL/kg. The LD50 is higher for most laboratory animals (20 mL/kg)

Similarly, propylene glycol is an approved food additive for human food as well. The exception is that it is prohibited for use in food for cats due to links to Heinz body anemia.

The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.

Acute Toxicity	X	Carcinogenicity	X
Skin Irritation/Corrosion	✓	Reproductivity	✓
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	×
Respiratory or Skin sensitisation	×	STOT - Repeated Exposure	<b>✓</b>
Mutagenicity	×	Aspiration Hazard	×

Legend:

X - Data either not available or does not fill the criteria for classification

Data available to make classification

# **SECTION 12 Ecological information**

# **Toxicity**

Cydectin Long Acting Injection for Sheep	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available

Chemwatch: **6069982** Page **10** of **12** 

Version No: **6.1.16.10** 

# **Cydectin Long Acting Injection for Sheep**

Issue Date: 11/01/2019 Print Date: 08/31/2021

	Endpoint	Test Duration (hr)	Species	Value	Source
moxidectin	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	336h	Algae or other aquatic plants	<5300mg/l	1
	EC50	72h	Algae or other aquatic plants	19300mg/l	2
propylene glycol	LC50	96h	Fish	>10000mg/l	2
	EC50	48h	Crustacea	>114.4mg/L	4
	EC50	96h	Algae or other aquatic plants	19000mg/l	2

Legend:

Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

# DO NOT discharge into sewer or waterways.

# Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
propylene glycol	LOW	LOW

#### Bioaccumulative potential

Ingredient	Bioaccumulation
propylene glycol	LOW (BCF = 1)

## Mobility in soil

Ingredient	Mobility
propylene glycol	HIGH (KOC = 1)

# **SECTION 13 Disposal considerations**

# Waste treatment methods

- Containers may still present a chemical hazard/ danger when empty.
- Return to supplier for reuse/ recycling if possible. Otherwise:

# ▶ If co

- If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
- Where possible retain label warnings and SDS and observe all notices pertaining to the product.
- Product / Packaging disposal

  DO NOT allow wash water from cleaning or process equipment to enter drains.

  It may be processed to collect all week water for treatment before disposed.
  - It may be necessary to collect all wash water for treatment before disposal.
  - In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
  - Where in doubt contact the responsible authority.
  - Recycle wherever possible or consult manufacturer for recycling options.
  - Consult State Land Waste Authority for disposal.
  - Bury or incinerate residue at an approved site.
  - Recycle containers if possible, or dispose of in an authorised landfill.

# **SECTION 14 Transport information**

# Labels Required

Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

# Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
moxidectin	Not Available
propylene glycol	Not Available

# Transport in bulk in accordance with the ICG Code

Product name	Ship Type
moxidectin	Not Available

Version No: **6.1.16.10** 

# **Cydectin Long Acting Injection for Sheep**

Issue Date: **11/01/2019**Print Date: **08/31/2021** 

Product name	Ship Type
propylene glycol	Not Available

# **SECTION 15 Regulatory information**

# Safety, health and environmental regulations / legislation specific for the substance or mixture

# moxidectin is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4  $\,$ 

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 7  $\,$ 

# propylene glycol is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule  $\bf 5$ 

Australian Inventory of Industrial Chemicals (AIIC)

# **National Inventory Status**

National Inventory	Status	
Australia - AIIC / Australia Non-Industrial Use	No (moxidectin)	
Canada - DSL	No (moxidectin)	
Canada - NDSL	No (moxidectin; propylene glycol)	
China - IECSC	No (moxidectin)	
Europe - EINEC / ELINCS / NLP	No (moxidectin)	
Japan - ENCS	No (moxidectin)	
Korea - KECI	No (moxidectin)	
New Zealand - NZIoC	Yes	
Philippines - PICCS	No (moxidectin)	
USA - TSCA	No (moxidectin)	
Taiwan - TCSI	Yes	
Mexico - INSQ	No (moxidectin)	
Vietnam - NCI	No (moxidectin)	
Russia - FBEPH	No (moxidectin)	
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.	

# **SECTION 16 Other information**

Revision Date	11/01/2019
Initial Date	05/13/2016

# SDS Version Summary

SDS Version Summary			
Version	Date of Update	Sections Updated	
5.1.1.1	10/17/2017	First Aid (skin)	
6.1.1.1	11/01/2019	One-off system update. NOTE: This may or may not change the GHS classification	
6.1.2.1	04/26/2021	Regulation Change	
6.1.3.1	05/03/2021	Regulation Change	
6.1.4.1	05/06/2021	Regulation Change	
6.1.5.1	05/10/2021	Regulation Change	
6.1.5.2	05/30/2021	Template Change	
6.1.5.3	06/04/2021	Template Change	
6.1.5.4	06/05/2021	Template Change	
6.1.6.4	06/07/2021	Regulation Change	
6.1.6.5	06/09/2021	Template Change	
6.1.6.6	06/11/2021	Template Change	
6.1.6.7	06/15/2021	Template Change	
6.1.7.7	06/17/2021	Regulation Change	
6.1.8.7	06/21/2021	Regulation Change	
6.1.8.8	07/05/2021	Template Change	
6.1.9.8	07/14/2021	Regulation Change	
6.1.10.8	07/19/2021	Regulation Change	
6.1.10.9	08/01/2021	Template Change	
6.1.11.9	08/02/2021	Regulation Change	
6.1.12.9	08/05/2021	Regulation Change	

Chemwatch: 6069982 Page 12 of 12 Issue Date: 11/01/2019 Version No: 6.1.16.10 Print Date: 08/31/2021

# **Cydectin Long Acting Injection for Sheep**

Version	Date of Update	Sections Updated
6.1.13.9	08/09/2021	Regulation Change
6.1.14.9	08/23/2021	Regulation Change
6.1.15.9	08/26/2021	Regulation Change
6.1.15.10	08/29/2021	Template Change
6.1.16.10	08/30/2021	Regulation Change

#### Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

#### **Definitions and abbreviations**

PC-TWA: Permissible Concentration-Time Weighted Average

PC-STEL: Permissible Concentration-Short Term Exposure Limit

IARC: International Agency for Research on Cancer

ACGIH: American Conference of Governmental Industrial Hygienists

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit。

IDLH: Immediately Dangerous to Life or Health Concentrations

ES: Exposure Standard OSF: Odour Safety Factor

NOAEL :No Observed Adverse Effect Level

LOAEL: Lowest Observed Adverse Effect Level

TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value

BCF: BioConcentration Factors BEI: Biological Exposure Index

AIIC: Australian Inventory of Industrial Chemicals

DSL: Domestic Substances List NDSL: Non-Domestic Substances List

IECSC: Inventory of Existing Chemical Substance in China

EINECS: European INventory of Existing Commercial chemical Substances

ELINCS: European List of Notified Chemical Substances

NLP: No-Longer Polymers

ENCS: Existing and New Chemical Substances Inventory

KECI: Korea Existing Chemicals Inventory

NZIoC: New Zealand Inventory of Chemicals

PICCS: Philippine Inventory of Chemicals and Chemical Substances

TSCA: Toxic Substances Control Act TCSI: Taiwan Chemical Substance Inventory INSQ: Inventario Nacional de Sustancias Químicas

NCI: National Chemical Inventory

FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

# This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.